Featured content in this Issue:
EQUULUS Therapeutics Emerges from Stealth with Non-Hallucinogenic Ibogaine Analog as Lead Candidate
Responses to ICER’s Draft Evidence Report on MDMA-Assisted Psychotherapy for PTSD
An Update on Health Canada’s Special Access Program
Beckley Psytech Publishes Phase I Study of Intranasal 5-MeO-DMT (BPL-003)
New NIH Funding Opportunity for Clinical Trials of Psychedelics for Chronic Pain in Older Adults
Clairvoyant Therapeutics Targets Conditional Marketing Authorisation in Canada and EU
Companies, organisations and drug candidates mentioned in this Bulletin: EQUULUS Therapeutics; EQL-101; EQL-201; Gilgamesh Pharmaceuticals; DemeRx; atai Life Sciences; Delix Therapeutics; CaaMTech; Lykos Therapeutics; Beckley Psytech; BPL-003; Compass Pathways; Clairvoyant Therapeutics.
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
